Opaleye Management reports $16,404 Grace Therapeutics common share purchase

GRCE•2026-10-01

Opaleye Management, a 10% owner of Grace Therapeutics, reported buying 7,849 common shares at $2.09, bringing its indirect stake through Opaleye, L.P. to 2,798,167 shares.

1. Share purchase

Opaleye Management reported buying 7,849 Grace Therapeutics common shares at $2.09 per share, for a total of $16,404. Its indirect stake through Opaleye, L.P. rose to 2,798,167 shares.

Sources

Opaleye Management reports $16,404 Grace Therapeutics common share purchase

Sec

Opaleye Management reports $16,404 Grace Therapeutics common share purchase

1. Share purchase

Related News

Elutia receives $8 million payment from Boston Scientific, is fully funded into 2029

US states challenge Corteva spinoff as bid to evade PFAS liabilities

Aureus Greenway Holdings files initial beneficial ownership statement for Michael Sinensky

Sources

Opaleye Management reports $16,404 Grace Therapeutics common share purchase

Cracker Barrel SVP, chief HR officer Donna Roberts disposes of 7,693 shares worth $404,805.66

Credo Technology CTO Cheng Chi Fung sells $5.03 million in common shares